Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with Follicular Lymphoma (FL)~* Confirmed diagnosis of Follicular lymphoma~* 18 years or above~* Verbal and written information about the study~Exclusion Criteria:~* No previous treatment for Follicular Lymphoma~* Clinical suspicion that the Follicular Lymphoma has transformed to aggressive lymphoma~* Several diseases such as malignancies etc.~* Screening laboratory values~* Current participation in any other interventional clinical study~* Breast feeding women or pregnant women~* Women of childbearing potential not willing to use adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg

Based on this trial design, predict the completion outcome and termination type (if applicable).